Top Medical Stocks To Buy For 2019

If you encounter a cloud of pot smoke backstage at a KISS show, it isn't coming from the bassist's dressing room.

Gene Simmons has abstained from drugs and alcohol in his more than four decades in KISS, unlike some of his bandmates. So it came as a surprise to many when cannabis cultivation and retail company Invictus MD Strategies Corp (OTC: IVITF) — which trades under the ticker "GENE" on the TSX Venture Exchange — announced that Simmons joined the company as its "chief evangelist officer."

The 68-year-old fire-breathing rocker spoke with Benzinga about the evolution of his views on marijuana. Hear his words and take heed.

 

Simmons Motivated By Money, Medicinal Value

For Simmons, it's a financial play: he didn't want to miss out on a rapidly expanding market, and he said he's come to understand that legislation is lagging the public opinion and medical possibilities of cannabis.

“I want lawmakers to really get educated on cannabis-related topics. I want them to get their information from people who don’t have a political agenda, like a 6-year little girl with epilepsy being prescribed cannabis-based products, which seem to be miraculously either minimizing or completely curing various ailments."

Top Medical Stocks To Buy For 2019: CSP Inc.(CSPI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Headlines about CSP (NASDAQ:CSPI) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CSP earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave headlines about the information technology services provider an impact score of 44.9831568716707 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Top Medical Stocks To Buy For 2019: PartnerRe Ltd.(PRE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Presearch (CURRENCY:PRE) traded down 2.1% against the U.S. dollar during the 1 day period ending at 11:00 AM Eastern on July 21st. Presearch has a total market capitalization of $18.94 million and $65,603.00 worth of Presearch was traded on exchanges in the last 24 hours. Over the last week, Presearch has traded 14.6% higher against the U.S. dollar. One Presearch token can now be purchased for $0.12 or 0.00001662 BTC on cryptocurrency exchanges including CoinExchange, YoBit and HitBTC.

Top Medical Stocks To Buy For 2019: Gap, Inc. (GPS)

Advisors’ Opinion:

  • [By Max Byerly]

    Element Capital Management LLC purchased a new stake in Gap Inc (NYSE:GPS) during the first quarter, according to its most recent filing with the SEC. The fund purchased 33,989 shares of the apparel retailer’s stock, valued at approximately $1,060,000.

  • [By Leo Sun]

    Over time, several of these secondary brands have become core growth drivers for their parent companies, offsetting the weaker results of the rest of the business. Let’s look at three rising stars that fit that description — American Eagles’ (NYSE:AEO) Aerie, Abercrombie & Fitch’s (NYSE:ANF) Hollister, and Gap’s (NYSE:GPS) Athleta.

  • [By JJ Kinahan]

    It was a different story for Gap Inc. (NYSE: GPS). The company’s stock fell more than 14.5 percent after it reported same-store sales climbed a little less than analysts had expected and earnings per share came in below expectations. Old Navy has been a driver for GPS, but same-store sales there rose 3 percent, down from 8 percent a year earlier.

  • [By Chris Lange]

    Gap Inc. (NYSE: GPS) was maintained as Hold at Deutsche Bank and assigned a $33 price target (versus a $32.95 close).

    Hormel Foods Corp. (NYSE: HRL) was maintained as Neutral at Buckingham Research and assigned a price target of $32 (versus a $35.42 close).

Top Medical Stocks To Buy For 2019: Antares Pharma, Inc.(ATRS)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

  • [By Joseph Griffin]

    News articles about Antares Pharma (NASDAQ:ATRS) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 45.2112654396991 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Stephan Byrd]

    Antares Pharma, Inc. (NASDAQ:ATRS) Director Jacques Gonella sold 300,000 shares of the firm’s stock in a transaction dated Wednesday, May 9th. The stock was sold at an average price of $2.47, for a total value of $741,000.00. Following the completion of the sale, the director now directly owns 11,936,413 shares of the company’s stock, valued at approximately $29,482,940.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Antares Pharma (ATRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *